Effects of intracerebroventricular injection of ketorolac and methylprednisolone on antioxidant activity in brain tissue of epileptic rats

Subject Areas : Experimental physiology and pathology

zohreh fazlelahi ¹ , Jahangir Kaboutari ² , Morteza Zendehdel ³ , Negar Panahi ⁴

1 - Department of Basic Sciences, Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran
2 -
3 - Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
4 - Department of Basic Sciences, Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran

Received: 2024-10-20 Accepted : 2024-12-30 Published : 2024-12-31

Keywords: Oxidative stress, Epilepsy, Ketorolac, Methylprednisolone, Rat,

Abstract :

Background & Aim: Epilepsy is a pervasive brain disorder and oxidative stress is considered as one of the most important mechanisms involved in epilepsy. Rather than treating epilepsy, current drugs merely control seizure symptoms. Therefore, identifying more effective medications for the treatment of epilepsy is of great importance. In this regard, the present study was carried out with the aim of investigating the effects of intracerebroventricular administration of ketorolac and methylprednisolone on the oxidative stress indices of the brain tissue of epileptic rats.

 

Materials and methods: In the current study, 48 female rats were randomly divided into 8 experimental groups to perform two experiments. In the first experiment, normal saline and ketorolac in doses of 7.5, 15, and 30 μg and in the second experiment, normal saline and methylprednisolone in doses of 0.15, 0.3, and 0.6 μg were injected, respectively, and acute epilepsy was also induced by intraperitoneal administration of pentylenetetrazole in rats. Half an hour after the injections, the rats were euthanized, and after separating the brain to check the indicators of oxidative stress, total antioxidant capacity, malondialdehyde, and nitric oxide levels were measured in hippocampal homogenous tissue.

 

Results: Based on the findings, the injection of ketorolac and methylprednisolone in a dose-dependent manner caused a significant increase in the total antioxidant capacity of the treatment groups compared to the control group (P<0.05). Also, the administration of different doses of both drugs significantly reduced the level of malondialdehyde and nitric oxide compared to the control group (P<0.05).

 

Conclusion: The results of this study showed that ketorolac and methylprednisolone probably have antioxidant effects and can be further investigated as potential treatment options for epilepsy and other diseases related to oxidative stress.

 

References:

1. Kovac S, Dinkova-Kostova AT, Abramov AY. The role of reactive oxygen species in epilepsy. React Oxyg Species. 2016;1(10.20455).
2. Adibhatla RM, Hatcher JF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxidants & redox signaling. 2010;12(1):125-69.
3. Meinardi H, Scott R, Reis R, On Behalf Of The Ilae Commission on the Developing World JS. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia. 2001;42(1):136-49.
4. Kazmi Z, Zeeshan S, Khan A, Malik S, Shehzad A, Seo EK, et al. Anti-epileptic activity of daidzin in PTZ-induced mice model by targeting oxidative stress and BDNF/VEGF signaling. Neurotoxicology. 2020;79:150-63.
5. Maiese K, Chong ZZ, Hou J, Shang YC. Oxidative stress: Biomarkers and novel therapeutic pathways. Experimental gerontology. 2010;45(3):217-34.
6. Buckley MM-T, Brogden RN. Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990;39:86-109.
7. Lashbrook JM, Ossipov MH, Hunter JC, Raffa RB, Tallarida RJ, Porreca F. Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1-and COX2-inhibitors in nerve-injured rats☆. Pain. 1999;82(1):65-72.
8. Chainy GB, Sahoo DK. Hormones and oxidative stress: an overview. Free Radical Research. 2020;54(1):1-26.
9. Hall ED. The neuroprotective pharmacology of methylprednisolone. Journal of neurosurgery. 1992;76(1):13-22.
10. Ocejo A, Correa R. Methylprednisolone. StatPearls. 2024.
11. Paxinos G, Watson C. The rat brain in stereotaxic coordinates in stereotaxic coordinates: Elsevier; 2007.
12. Fazlelahi Z, Kaboutari J, Zendehdel M, Panahi N. Effects of Intracerebroventricular Injection of the Steroidal and Non-Steroidal Anti-Inflammatory Drugs on the Seizures during the Estrous Cycle in Rat. Archives of Razi Institute. 2023;78(3):807.
13. Kaboutari J, Zendehdel M, Habibian S, Azimi M, Shaker M, Karimi B. The antiepileptic effect of sodium valproate during different phases of the estrous cycle in PTZ-induced seizures in rats. Journal of physiology and biochemistry. 2012;68:155-61.
14. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of “antioxidant power”: the FRAP assay. Analytical biochemistry. 1996;239(1):70-6.
15. Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates. Clinical science (London, England: 1979). 1993;84(4):407-12.
16. Schmedes A, Hølmer G. A new thiobarbituric acid (TBA) method for determining free malondialdehyde (MDA) and hydroperoxides selectively as a measure of lipid peroxidation. Journal of the American Oil Chemists' Society. 1989;66(6):813-7.
17. Yucel AA, Gulen S, Dincer S, Yucel AE, Yetkin GI. Comparison of two different applications of the Griess method for nitric oxide measurement. J Exp Integr Med. 2012;2(1):167.
18. Moshé SL, Perucca E, Ryvlin P, Tomson T. Epilepsy: new advances. The Lancet. 2015;385(9971):884-98.
19. Marrocco I, Altieri F, Peluso I. Measurement and clinical significance of biomarkers of oxidative stress in humans. Oxidative medicine and cellular longevity. 2017;2017(1):6501046.
20. Kusano C, Ferrari B. Total antioxidant capacity: a biomarker in biomedical and nutritional studies. J Cell Mol Biol. 2008;7(1):1-15.
21. Singh Z, Karthigesu IP, Singh P, Rupinder K. Use of malondialdehyde as a biomarker for assessing oxidative stress in different disease pathologies: a review. Iranian Journal of Public Health. 2014;43(Supple 3):7-16.
22. Malinski T. Nitric oxide and nitroxidative stress in Alzheimer's disease. Journal of Alzheimer's disease. 2007;11(2):207-18.
23. Schoenberger SD, Kim SJ, Sheng J, Calcutt MW. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%. Jama Ophthalmology. 2014;132(2):150-4.
24. Yoshino T, Noguchi M, Okutsu H, Kimoto A, Sasamata M, Miyata K. Celecoxib does not induce convulsions nor does it affect GABAA receptor binding activity in the presence of new quinolones in mice. European journal of pharmacology. 2005;507(1-3):69-76.
25. Clossen BL, Reddy DS. Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2017;1863(6):1519-38.
26. Stichtenoth DO, Frölich JC. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs. 2003;63:33-45.
27. Bagriyanik HA, Ozogul C, Alaygut E, Gokmen N, Kucukguclu S, Gunerli A, et al. Neuroprotective effects of ketorolac tromethamine after spinal cord injury in rats: an ultrastructural study. Advances in therapy. 2008;25:152-8.
28. Esen E, Taşar F, Akhan O. Determination of the anti-inflammatory effects of methylprednisolone on the sequelae of third molar surgery. Journal of oral and maxillofacial surgery. 1999;57(10):1201-6.
29. Cortivo R, Brun P, Cardarelli L, O'Regan M, Radice M, Abatangelo G, editors. Antioxidant effects of hyaluronan and its α-methyl-prednisolone derivative in chondrocyteand cartilage cultures. Seminars in arthritis and rheumatism; 1996: Elsevier.
30. Arif A, Hussain S, Rajput SN, Malik HN, Naqvi F, Jabeen A, et al. Nanoscale Lipid-Methylprednisolone Conjugates: Effective Anti-Inflammatory, Antioxidant, and Analgesic Agents. Journal of Drug Delivery Science and Technology. 2024:106251.
31. Rainsford K. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). The American journal of medicine. 1999;107(6):27-35.